Novakand Pharma AB (publ) (FRA:3EE0)

Novakand Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	-	-	0.09
Revenue Growth (YoY)	-	-	-	-	-	-97.20%
Cost of Revenue	-	-	-	-	-	0.03
Gross Profit	-	-	-	-	-	0.06
Selling, General & Admin	6.23	6.22	8.09	7.08	4.33	5.54
Research & Development	28.28	39.95	57.99	45.61	42.63	39.28
Other Operating Expenses	-0.01	-0.01	-	-	-0	-0.13
Operating Expenses	34.5	46.16	66.08	52.69	46.96	44.69
Operating Income	-34.5	-46.16	-66.08	-52.69	-46.96	-44.62
Interest Expense	-	-	-	-0.12	-0.02	-1.1
Interest & Investment Income	0.59	1.6	0.28	0.07	-	-
Currency Exchange Gain (Loss)	-	-	0.45	-0.09	-0.25	0.11
Other Non Operating Income (Expenses)	0	-	0.46	0.34	1.54	2.35
EBT Excluding Unusual Items	-33.9	-44.57	-64.89	-52.48	-45.69	-43.26
Gain (Loss) on Sale of Assets	-	-	-	-	-	2.76
Pretax Income	-51.9	-44.57	-64.89	-52.48	-45.69	-40.5
Net Income	-51.9	-44.57	-64.89	-52.48	-45.69	-40.5
Net Income to Common	-51.9	-44.57	-64.89	-52.48	-45.69	-40.5
Shares Outstanding (Basic)	121	115	80	58	56	36
Shares Outstanding (Diluted)	121	115	80	58	56	36
Shares Change (YoY)	17.04%	44.85%	36.90%	3.91%	54.18%	82.68%
EPS (Basic)	-0.43	-0.39	-0.81	-0.90	-0.82	-1.12
EPS (Diluted)	-0.43	-0.39	-0.81	-0.90	-0.82	-1.12
Free Cash Flow	-35.66	-58.53	-55.67	-47.56	-44.13	-38.99
Free Cash Flow Per Share	-0.29	-0.51	-0.70	-0.82	-0.79	-1.07
Gross Margin	-	-	-	-	-	70.00%
Operating Margin	-	-	-	-	-	-49580.00%
Profit Margin	-	-	-	-	-	-45000.00%
Free Cash Flow Margin	-	-	-	-	-	-43320.00%
EBITDA	-	-43.16	-63.08	-52.33	-46.64	-43.05
D&A For EBITDA	-	3	3	0.36	0.32	1.58
EBIT	-34.5	-46.16	-66.08	-52.69	-46.96	-44.62

Source: S&P Global Market Intelligence. Standard template. Financial Sources.